HomeBUSINESS
BUSINESS

Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand
(Oct.19.2018)

Ayumi Pharmaceutical is missing out on a big opportunity. Failing to capitalize on stronger-than-expected demand for Japan’s first and only Enbrel (etanercept) biosimilar it launched in May, the company is now asking medical institutions to stop its new prescriptions, while calling on existing prescribers to limit its use to certain patients ...
(LOG IN FOR FULL STORY)